| Edward George Hames Iii, MD | |
|
800 West Ave S, La Crosse, WI 54601 | |
| (608) 785-0940 | |
| Not Available |
| Full Name | Edward George Hames Iii |
|---|---|
| Gender | Male |
| Speciality | Neurological Surgery |
| Location | 800 West Ave S, La Crosse, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851309637 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 26842 (Minnesota) | Secondary |
| 207T00000X | Neurological Surgery | 68845 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Edward George Hames Iii, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (715) 838-5222 | Edward George Hames Iii, MD 800 West Ave S, La Crosse, WI 54601 Ph: (608) 785-0940 |
News Archive
Research studies show that Black patients can be subjected to wait times 30% longer than other patients at doctors' offices and other healthcare facilities, leaving little doubt about the biased nature of healthcare scheduling systems.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of the PROstate Advanced Cancer Treatment (PROACT) Phase 2 proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib in patients with advanced prostate cancer.
Chronic Obstructive Pulmonary Disease (COPD), a condition impacting nearly 24 million Americans, is often associated with disease-specific fears and avoidance of physical activity. Little is known of the structural brain processes that occur in COPD patients. A study published in the February issue of the journal CHEST found that patients with COPD demonstrated gray matter decreases in areas of the brain that process breathlessness, fear and sensitivity to pain.
Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.
A new research study by Queen's University Belfast launched today in partnership with six other UK-based universities has found significant inequalities in child welfare across the UK, with children in the most deprived areas more likely than those in the least deprived to become involved in the child protection system.
› Verified 5 days ago
Michael J Ebersold, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Humbert G Sullivan, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Walter J Faillace, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 Fax: 608-775-4467 | |
Mark K Stevens, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 800 West Ave S, La Crosse, WI 54601 Phone: 608-791-9831 Fax: 608-791-9814 | |
Kerry T White, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 Fax: 608-775-4429 | |
Jerry A Davis, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Dr. Douglas George Hughes, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 |